Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.